ICTM logo
Andrew Nunn, Associate Director and Chair of Infections Research Theme

Andrew Nunn joined the MRC’s Tuberculosis & Chest Diseases Unit as a statistician in 1966. During the next 20 years he was directly involved in the design, conduct and analysis of the programme of trials conducted under the leadership of Professors Wallace Fox and Denny Mitchison in East Africa, Hong Kong and Singapore which led to the worldwide adoption of short course chemotherapy for tuberculosis.

Following the closure of that unit he joined the MRC’s Uganda AIDS Programme which researched the dynamics of the HIV epidemic in a rural African environment. On his return to the UK he became head of the Division Without Portfolio within the newly formed MRC Clinical Trials Unit with responsibility for developing trials in neglected areas.

Currently, he is an investigator and senior statistician on three international Phase III trials of tuberculosis treatment one of which, STREAM, is the first Phase III trial in multidrug-resistant TB.

Selected publications:

McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, Jentsch U, Pool R, Chisembele M, Kapiga S, Mutemwa R, Vallely A, Palanee T, Sookrajh Y, Lacey CJ, Darbyshire J, Grosskurth H, Profy A, Nunn A, Hayes R, Weber J. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010 Oct 16;376(9749):1329-37

Lienhardt C, Cook SV, Burgos M, Yorke-Edwards V, Rigouts L, Anyo G, Kim SJ, Jindani A, Enarson DA, Nunn AJ; Study C Trial Group. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. JAMA. 2011 Apr 13;305(14):1415-23.

Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C, Peckham D, Davies CW, Ali N, Kinnear W, Bentley A, Kahan BC,  Wrightson JM, Davies HE, Hooper CE, Lee YC, Hedley EL, Crosthwaite N,  Choo L, Helm EJ, Gleeson FV, Nunn AJ, Davies RJ. Intrapleural Use of  Tissue Plasminogen Activator and DNase in Pleural Infection. N Engl J Med 2011 Aug 11;365(6):518-26

Phillips PP, Fielding K, Nunn AJ. An Evaluation of Culture Results during Treatment for Tuberculosis as Surrogate Endpoints for Treatment Failure and Relapse. PLoS One. 2013; 8(5): e63840.

Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PPJP, Nunn AJ. Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis. N Engl J Med. 2014; Epub 2014/09/10

Nunn AJ, Rusen I, Van Deun A, Torrea G, Phillips PP, Chiang CY, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials. 2014;15(1):353. Epub 2014/09/10.

Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. . N Engl J Med 2014; 371(17):1599-1608

Image of Andrew Nunn

Research interests:

  • Treatment of drug sensitive and multidrug-resistant TB
  • Trials in neglected disease areas
  • Trials in developing countries
  • Non-inferiority trials

Research areas:

  • Dermatology
  • Diabetes
  • Multiple sclerosis and pain management
  • Respiratory disease
  • Tuberculosis

IRIS profile